echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > China, Japan to jointly develop a new AIDS gene therapy vaccine

    China, Japan to jointly develop a new AIDS gene therapy vaccine

    • Last Update: 2020-07-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    "China-Japan cooperation in the development of AIDS gene therapy vaccine project"signed in Shenzhen25Chinese and Japanese researchers will jointly develop a new AIDS gene therapy vaccine,and plan to market within four yearsThe global epidemic of AIDS has seriously threatened the safety of human lifeU.NSecretary-General Ban Ki-moon said in a speech to the General Assembly on May 2in
    the past 2
    ,65 million people have been infected with AIDS,25 million people have died
    , there are 40 million people living with AIDS, about 8,000 people die every day from AIDS-relateddiseasesIt is understood that, although scientists in various countries have invested a lot of effort spent on vaccine research and development, there are currently more than 1
    2
    0 AIDS vaccines in the international clinical trials, including AIDS gene therapy vaccine there are 60 or 70, but there is still no effective vaccine products to market Zeng Yi, a member of
    the Chinese Academy of Sciences and chief scientist of the Center for Sexually Transmitted Diseases and AIDS Prevention and Control, a china disease prevention and control center, served as the chief scientist of the project He said: "There is a consensus all over the world, who want to solve the AIDS prevention and control issues alone is difficult, must be international cooperation, especially developed and developing countries to join forces, in order to do." he said that the vaccine to be developed by China and Japan is a new type of "Sendai virus-Gag recombinant", using the Sendai virus carrier, which was successfully developed by Japan Biocarrier Co., Ltd over the years, and carried the Gag gene of the HIV strain Animal experiments have shown that this recombination can induce the body to produce a very high level of anti-HIV-specific cellular immune response This cooperation takes the form of of Japan Biocarrier Co., Ltd., of the China Center for Disease Control and Prevention, and Beijing University of Technology to Shenzhen Saibaino Gene Technology Co., Ltd to transfer all the technology , patents and information of the "Sendai virus-Gag recombinant" in advance, led by Sabeno to continue post-development, clinical trials, industrialization and marketing Shenzhen Sebaino Gene Technology has successfully developed and launched the world's first approved gene therapy drug In 2003 the company independently developed the "recombinant person P53 adenovirus injection" (
    product named "now and again") obtained the national new drug certificate "
    this cooperation will give full play to the best in the field of technical research , clinical trials and industrial production, and strive to market the product within 4 years, " said Dr Peng Zhaoxuan, chairman of the company (
    reprinted from "Xinhuanet")
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.